Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT02017197

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02017197
  • WHO UTN U1111-1155-4833
Other papers using this trial's data
  • Examining therapeutic equivalence between branded and generic warfarin in Brazil: The WARFA crossover randomized controlled trial PloS one, 2021 DOI, PubMed 33793580, PMC8016229 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02017197. Randomized; triple masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2016-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
Acronym
WARFA
Intervention (Drug)
Marevan®
Intervention (Drug)
generic warfarin #1
Intervention (Drug)
generic warfarin #2
Lead sponsor
Federal University of São Paulo (class: other)
Collaborator
Fundação de Amparo à Pesquisa do Estado de São Paulo (class: other government)

Record details

Record id
cardio:ct-nct02017197
Content hash
54e66a27ad0186610548197e281feb280ea6681fa9e5febeb55cd1986532edc9